Skip to main content
Premium Trial:

Request an Annual Quote

Curetis Gains Access to Additional €5 Million Debt Financing for COVID-19 R&D

NEW YORK – OpGen said Thursday that its subsidiary Curetis will have access to an additional €5 million ($5.65 million) debt financing tranche that it plans to use for research and development activities related to the COVID-19 pandemic.

The debt financing facility was originally placed in 2016 and amended in 2019, and the additional €5 million will be used to co-fund R&D programs related to COVID-19 across "several of the platforms and the entire product portfolio" of Curetis and Ares Genetics, another subsidiary of OpGen, the company said in a statement. 

Curetis can draw down the additional tranche within nine months. It will have a five-year term to maturity where interest payments during the term are compounded and payable once the principal amount of the tranche has matured.

OpGen CEO and Curetis Managing Director Oliver Schacht said the funding will allow continued development of the Unyvero A50 and A30 RQ platforms, with particular focus on how they can be applied to COVID-19.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.